Th1/Th2与PCT检测在感染性疾病诊断中的临床应用

病原微生物引起的感染性疾病是临床中极为常见的一类疾病,此类疾病的预后主要取决于感染的病原微生物类型及疾病的严重程度。早期诊断和积极干预可在很大程度上改善感染性疾病患者的预后。因此,快速、有效地识别感染的病原微生物并对其进行靶向治疗,避免抗生素的滥用显得尤为重要。Th1/Th2在感染性疾病中的作用越来越得到重视,而降钙素原(PCT)是临床感染性疾病诊断和鉴别诊断的早期指标,且具有高度的敏感性和特异性。Th1/Th2和PCT的联合检测对感染性疾病的诊断、病情评估和疗效监测都具有重要的意义。     

综述与专论: 树鼩病毒感染模型的研究新进展

病毒感染引起的疾病接近中国主要传染病发病率的一半,也是传染病致死的主要病因。建立与人类亲缘关系较近、方便有效的感染人类病毒的动物模型,对了解病毒的生物学特性、感染致病机理及制定有效防控措施具有重要意义。树鼩作为灵长类动物的近亲,与人类在生理生化、基因组学等方面的相似性远高于大鼠、小鼠等常用啮齿类实验动物,并具有个体小、便于实验操作、饲养成本低、能感染多种人类病毒等特点,作为动物模型在病毒感染性疾病研究中突显优势和潜能。本文从地区分布、进化、生物学特性等方面,阐述了树鼩作为动物模型应用于病毒感染性疾病研究的优势,包括在乙型肝炎病毒、甲型肝炎病毒,及其他病毒感染疾病研究中的进展。     

结核分枝杆菌感染动物模型的研究进展

人类结核病位居单一病原引起死亡的严重传染病之首,结核分枝杆菌是其主要病原.尽管结核分枝杆菌可引起许多种动物感染并患病,但人类是其主要宿主.动物模型作为研究人类疾病的标准化工具,虽然不能完全模拟人类结核病的整个过程,但可成为研究结核病的有用工具,有助于研究其发病机制、治疗过程及宿主对病原的免疫病理学反应.由于不同种类动物...     

人类疾病动物模型在生物技术研发中的应用

人类疾病动物模型具有与人类疾病相似的症状或病理变化。应用动物模型是现代医学认识生命科学客观规律的重要实验方法。用实验结果推测人类疾病的发生和发展规律,研究有效的防治措施。本主要介绍在生物技术的开发中实验动物的选择和传染性疾病的动物模型。     

MERS-CoV动物模型研究进展

中东呼吸综合征冠状病毒(Middle East respiratory syndrome coronavirus,MERS-CoV)最早发现于2012年,是继严重急性呼吸窘迫综合征冠状病毒(severe acute respiratory syndrome coronavirus,SARS-CoV)之后,引起人类严重感染的又一种重要冠状病毒。对于该种新发现、致病性强、病死率高的感染性疾病,开发有效的动物模型对于研究疾病的发病过程、致病机理、评估预防与治疗措施的效果等具有重要理论和现实意义。到目前为止,非人灵长类动物如恒河猴、狨猴,小型动物如小鼠、仓鼠、雪貂、新西兰白兔等均被尝试作为MERS-CoV感染的动物模型。其中一些已经用于评估疫苗或药物的干预效果。本文就MERS-CoV动物模型研究进展作一综述。     

空肠弯曲菌感染动物模型的研究进展

空肠弯曲菌是一种全球关注的人兽共患病原菌,感染后可引起人和动物多种疾病。动物模型是开展致病机理、疫苗评价和药物开发等研究的基础。空肠弯曲菌由于培养条件苛刻以及感染实验动物的疾病相似性、经济性和重复性等因素,仍缺乏良好的感染动物模型,其致病机理迄今尚不清楚。本文对已报道的空肠弯曲菌感染实验动物模型进行综述。     

宠物对人类健康的潜在威胁

宠物是多种人兽共患病病原的宿主和传播媒介,由于传统宠物、另类宠物和进口宠物的增多,宠物来源的感染性疾病有了高发的趋势。本文总结了狗、猫、啮齿类、鸟类、鱼和爬行类宠物可能带有的人兽共患病病原,引发的疾病和传播途径。并概括了防控宠物源性感染性疾病的防控措施。     

树鼩独立换气笼具的设计

目的设计研究一种满足于树鼩感染性疾病动物模型实验生物安全要求的独立换气专用隔离笼具。方法根据树驹的生物学特性、实验生物安全要求及有关实验动物笼具标准进行设计。结果该笼舍完全适用于感染性疾病实验树鼢的饲养和实验操作。结论该笼具能达到维护实验动物福利,保证实验动物质量,保障人身健康,保护环境的要求,对于使用树鼩开展人类重大传染病研究具有广泛的应用价值和市场前景。     

结核分枝杆菌感染实验模型

结核分枝杆菌是引起人结核病的主要病原,全世界约有1/3人口感染结核分枝杆菌。尽管该病原可感染并引起许多动物疾病,但人类是其中心宿主。为研究结核分枝杆菌的致病机理及宿主对本病原的保护性和免疫病理学反应,选择合适的动物模型非常必要。本文阐述了结核病研究中常用的实验模型及各种模型的优缺点。实验模型的合理应用将促进我们对结核病的认识,从中获取的资料将有助于我们发现更好的预防和治疗方案。     

基因敲除小鼠在疾病研究中的应用

人类疾病动物模型在揭示人类疾病的发生机制或建立治疗方法中具有极重要的作用。然而,许多疾病难以用人工诱发的方法制造动物模型,还有许多疾病在实验动物身上不发生,而难以通过自发或人工定向培育的方法获得动物模型。基因敲除技术的出现,为人类精确地研究基因与疾病的直接关系提供了可能,而且可以在个体发生的每个阶段中进行遗传功能的分析。综述了基因敲除小鼠模型在几种疾病研究中的研究与应用及其发展前景。     

Diversifying animal models: the use of hispid cotton rats (Sigmodon hispidus) in infectious diseases

The hispid cotton rat (Sigmodon hispidus) has been a longstanding laboratory animal model of infectious diseases. In this review, the most common usage of hispid cotton rats as models of infectious diseases is discussed in detail and all organisms, which have been shown to infect cotton rats, are listed. A state of the art overview is given on handling and maintenance of hispid cotton rats as well as experimental techniques such as narcosis and blood withdrawal. Most importantly, through the development of new reagents, the hispid cotton rat can be used to study immune responses against the respective pathogen. Hispid cotton rat cytokine and chemokine genes have been sequenced and cotton rat specific antibodies and cell lines have been produced which in connection with the establishment of immunological methods should facilitate the use of hispid cotton rats as animal models in the pathogenesis of infectious diseases.     

结核病动物模型研究进展

结核病是由结核分枝杆菌感染引起的传染病,是危害人类健康的主要传染病之一。动物模型已经成为研究人类传染病的标准化工具。虽然对于结核分枝杆菌而言并没有真正意义的动物资源,但由于不同种类的动物,对分枝杆菌的敏感性不一样,因此可以成为结核病研究的有利工具。结核病最常用的实验动物模型包括小鼠、兔和豚鼠。每种动物有其自身特点,但并不能完全模拟人类疾病。通过建立结核病的动物模型,可以大大增加我们对疾病的病因、毒力和发病机制的理解。除了这三种模型外,非人灵长类也常被用于结核病的研究。本文总结了这几种结核病模型的研究状况。     

The guinea pig as a model of infectious diseases

The words 'guinea pig' are synonymous with scientific experimentation, but much less is known about this species than many other laboratory animals. This animal model has been used for approximately 200 y and was the first to be used in the study of infectious diseases such as tuberculosis and diphtheria. Today the guinea pig is used as a model for a number of infectious bacterial diseases, including pulmonary, sexually transmitted, ocular and aural, gastrointestinal, and other infections that threaten the lives of humans. Most studies on the immune response to these diseases, with potential therapies and vaccines, have been conducted in animal models (for example, mouse) that may have less similarity to humans because of the large number of immunologic reagents available for these other species. This review presents some of the diseases for which the guinea pig is regarded as the premier model to study infections because of its similarity to humans with regard to symptoms and immune response. Furthermore, for diseases in which guinea pigs share parallel pathogenesis of disease with humans, they are potentially the best animal model for designing treatments and vaccines. Future studies of immune regulation of these diseases, novel therapies, and preventative measures require the development of new immunologic reagents designed specifically for the guinea pig.     

The pig: a model for human infectious diseases

An animal model to study human infectious diseases should accurately reproduce the various aspects of disease. Domestic pigs (Sus scrofa domesticus) are closely related to humans in terms of anatomy, genetics and physiology, and represent an excellent animal model to study various microbial infectious diseases. Indeed, experiments in pigs are much more likely to be predictive of therapeutic treatments in humans than experiments in rodents. In this review, we highlight the numerous advantages of the pig model for infectious disease research and vaccine development and document a few examples of human microbial infectious diseases for which the use of pigs as animal models has contributed to the acquisition of new knowledge to improve both animal and human health.     

Tree shrew (Tupaia belangeri) as a novel laboratory disease animal model

The tree shrew (Tupaia belangen) is a promising laboratory animal that possesses a closer genetic relationship to primates than to rodents.In addition,advantages such as small size,easy breeding,and rapid reproduction make the tree shrew an ideal subject for the study of human disease.Numerous tree shrew disease models have been generated in biological and medical studies in recent years.Here we summarize current tree shrew disease models,including models of infectious diseases,cancers,depressive disorders,drug addiction,myopia,metabolic diseases,and immune-related diseases.With the success of tree shrew transgenic technology,this species will be increasingly used in biological and medical studies in the future.     

Lentiviral vectors for treating and modeling human CNS disorders

Vectors based on lentiviruses efficiently deliver genes into many different types of primary neurons from a broad range of species including man and the resulting gene expression is long term. These vectors are opening up new approaches for the treatment of neurological diseases such as Parkinson's disease (PD), Huntington's disease (HD), and motor neuron diseases (MNDs). Numerous animal studies have now been undertaken with these vectors and correction of disease models has been obtained. Lentiviral vectors also provide a new strategy for in vivo modeling of human diseases; for example, the lentiviral-mediated overexpression of mutated human alpha-synuclein or huntingtin genes in basal ganglia induces neuronal pathology in animals resembling PD and HD in man. These vectors have been refined to a very high level and can be produced safely for the clinic. This review will describe the general features of lentiviral vectors with particular emphasis on vectors derived from the non-primate lentivirus, equine infectious anemia virus (EIAV). It will then describe some key examples of genetic correction and generation of genetic animal models of neurological diseases. The prospects for clinical application of lentiviral vectors for the treatment of PD and MNDs will also be outlined.     

Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases

This review provides an overview of studies employing particle-mediated epidermal delivery (PMED) or the gene gun to administer DNA vaccines for infectious diseases in preclinical studies employing large animal models and in human clinical trials. It reviews the immunogenicity and protective efficacy of PMED DNA vaccines in nonhuman primates and swine and studies that have directly compared the effectiveness of PMED in these large animal models to existing licensed vaccines and intramuscular or intradermal delivery of DNA vaccines with a needle. Various clinical trials employing PMED have been completed and an overview of the immunogenicity, safety, and tolerability of this approach in humans is described. Finally, efforts currently in progress for commercial development of particle-mediated DNA vaccines are discussed.     

Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents

Animal infection models in the pharmacokinetic/pharmacodynamic (PK/PD) evaluation of antimicrobial therapy serve an important role in preclinical assessments of new antibiotics, dosing optimization for those that are clinically approved, and setting or confirming susceptibility breakpoints. The goal of animal model studies is to mimic the infectious diseases seen in humans to allow for robust PK/PD studies to find the optimal drug exposures that lead to therapeutic success. The PK/PD index and target drug exposures obtained in validated animal infection models are critical components in optimizing dosing regimen design in order to maximize efficacy while minimize the cost and duration of clinical trials. This review outlines the key components in animal infection models which have been used extensively in antibiotic discovery and development including PK/PD analyses.     

光动力疗法治疗感染性疾病的动物模型

光动力疗法(photodynamic therapy,PDT)是利用特定波长的激发光照射生物靶标上的光敏剂,从而产生活性氧并有效杀伤多种耐药病原体的新型治疗方式,具有作用广、安全可控、不易耐受等优点。大量体外实验已证实了PDT疗效,但目前动物实验数据较少,且治疗参数不一,一定程度上影响了PDT在临床治疗中的广泛应用。本文综述近年来PDT用于体内抗感染治疗的动物模型构建、治疗方案设计等方面的研究进展,为未来PDT抗感染研究及临床应用提供参考。     

The use of recombinant human interleukin-2 in treating infectious diseases

Data from animal models indicate that interleukin-2 is potentially valuable in the treatment of a variety of infectious diseases of viral, fungal, protozoal, bacterial, and mycobacterial origin. The role of interleukin-2 in resistance to infection with human immunodeficiency virus or Mycobacterium Ieprae (the causative agent of leprosy) has recently been studied in detail. Data from animal models and clinical trials indicate that relatively low doses of interleukin-2 effectively stabilize or reverse the course of these infections. The recent characterization of Thi and Th2 helper T cells, and their relationship to the control of infectious diseases, are revealing the mechanisms involved in producing disease. Increased understanding of these mechanisms may help extend interleukin-2 therapy to other clinical applications.